RxDoctor Payments Data

Maria Levin

Family · Brooklyn, NYNPI 1679946198

Payments from drug & device makers

$2,707in general payments, 2019–2025

Across 72 payments — averaging $37.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$914
  • Regeneron Healthcare Solutions, Inc.$397
  • Arcutis Biotherapeutics, Inc.$339
  • LEO Pharma Inc.$306
  • Organon$209
  • AbbVie$186
  • plus $356 from 8 others

What the payments were for

  • Speaking & faculty fees$301%
  • Food & beverage$2,66298%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,707 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$257,721
Medicare patients
324
Services billed
38,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpzeluraRuxolitinib Phosphate29$56,535
Calcipotriene26$4,473
Clobetasol Propionate65$3,391
Ketoconazole140$2,217
Gentamicin Sulfate53$1,942
Ammonium Lactate111$1,934
Hydrocortisone15$1,867
Halobetasol Propionate28$1,388
Clindamycin Phosphate47$1,326
Triamcinolone Acetonide98$933
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet22$768
Mometasone Furoate45$709
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip45$674
Mupirocin112$614
Nystatin53$592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$914$56,53529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →